{"created":"2023-05-15T16:30:35.993520+00:00","id":1787,"links":{},"metadata":{"_buckets":{"deposit":"f110591a-2339-47de-bce0-bd2fa3f2be2f"},"_deposit":{"created_by":2,"id":"1787","owners":[2],"pid":{"revision_id":0,"type":"depid","value":"1787"},"status":"published"},"_oai":{"id":"oai:nagasaki-u.repo.nii.ac.jp:00001787","sets":["8:9"]},"author_link":["8390","8385","8380","8383","8388","8389","8393","8381","8384","8387","8378","8391","8386","8392","8382","8394","8379"],"item_2_biblio_info_6":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2019-06","bibliographicIssueDateType":"Issued"},"bibliographicPageEnd":"8","bibliographicPageStart":"1","bibliographicVolumeNumber":"132","bibliographic_titles":[{"bibliographic_title":"Lung Cancer"}]}]},"item_2_description_4":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Objectives: To evaluate the efficacy and safety, we conducted a randomized phase II study of pemetrexed (Pem) versus Pem + bevacizumab (Bev) for elderly patients \nwith non-squamous non-small cell lung cancer (NSqNSCLC). Patients and methods: The eligibility criteria were as follows: NSqNSCLC, no prior therapy,stage IIIB/IV disease or postoperative recurrence, age: ?75 years, performance status (PS): 0?1, and adequate bone marrow function. The patients were randomly assigned (1:1 ratio)to receive Pem or Pem + Bev. The primary endpoint was progression-free survival (PFS).The secondary endpoints were the response rate, OS, toxicities, and cost-effectiveness. \nResults: Forty-one patients were enrolled and 40 (20 from each group) were assessable. \nTheir characteristics were as follows: male/female = 23/17; median age (range) = 78 (75?83); stage IIIB/IV/postoperative recurrence = 1/30/9; PS 0/1 = 11/29. All cases involved adenocarcinoma.There was no significant intergroup difference in PFS and the median PFS (95% confidence interval)\n values of the Pem and Pem + Bev groups were 5.4 (3.0?7.4) and 5.5 (3.6?9.9) months, respectively (p = 0.66). The response rate was significantly higher in the Pem + Bev group(15% vs. 55%, p = 0.0146), and there was no significant difference in OS (median: 16.0 vs. 16.4 months, p = 0.58). Grade 3 and 4 leukopenia, neutropenia,and thrombocytopenia were seen in 10 and 30, 20 and 55, and 5 and 5 cases, respectively.\n Drug costs were higher in the Pem + Bev group (median: 1,522,008 vs. 3,368,428 JPY, p = 0.01). No treatment-related deaths occurred. Conclusions: Adding Bev to Pem did not result in improved survival in the elderly NSqNSCLC patients. Compared with Pem + Bev, Pem monotherapy had similar effects on survival, a more favorable toxicity profile, and was more cost-effective in elderly NSqNSCLC patients. Pem monotherapy might be one of the optional regimen for NSqNSCLC patients aged ?75 years.","subitem_description_type":"Abstract"}]},"item_2_description_63":{"attribute_name":"引用","attribute_value_mlt":[{"subitem_description":"Lung Cancer, 132, pp.1-8; 2019","subitem_description_type":"Other"}]},"item_2_publisher_33":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"Elsevier B.V."}]},"item_2_relation_12":{"attribute_name":"DOI","attribute_value_mlt":[{"subitem_relation_type":"isVersionOf","subitem_relation_type_id":{"subitem_relation_type_id_text":"10.1016/j.lungcan.2019.01.008","subitem_relation_type_select":"DOI"}}]},"item_2_rights_13":{"attribute_name":"権利","attribute_value_mlt":[{"subitem_rights":"c 2019 Elsevier B.V. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/"}]},"item_2_source_id_7":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"01695002","subitem_source_identifier_type":"ISSN"}]},"item_2_version_type_16":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_ab4af688f83e57aa","subitem_version_type":"AM"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Fukuda, Minoru"}],"nameIdentifiers":[{"nameIdentifier":"8378","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Kitazaki, Takeshi"}],"nameIdentifiers":[{"nameIdentifier":"8379","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Ogawara, Daiki"}],"nameIdentifiers":[{"nameIdentifier":"8380","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Ichiki, Masao"}],"nameIdentifiers":[{"nameIdentifier":"8381","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Mukae, Hiroshi"}],"nameIdentifiers":[{"nameIdentifier":"8382","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Maruyama, Riichiroh"}],"nameIdentifiers":[{"nameIdentifier":"8383","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Nakagaki, Noriaki"}],"nameIdentifiers":[{"nameIdentifier":"8384","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Shimada, Midori"}],"nameIdentifiers":[{"nameIdentifier":"8385","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Ikeda, Takaya"}],"nameIdentifiers":[{"nameIdentifier":"8386","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Kishimoto, Junji"}],"nameIdentifiers":[{"nameIdentifier":"8387","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Harada, Taishi"}],"nameIdentifiers":[{"nameIdentifier":"8388","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Seto, Takashi"}],"nameIdentifiers":[{"nameIdentifier":"8389","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Ebi, Noriyuki"}],"nameIdentifiers":[{"nameIdentifier":"8390","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Takayama, Koichi"}],"nameIdentifiers":[{"nameIdentifier":"8391","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Okamoto, Isamu"}],"nameIdentifiers":[{"nameIdentifier":"8392","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Ichinose, Yukito"}],"nameIdentifiers":[{"nameIdentifier":"8393","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Sugio, Kenji"}],"nameIdentifiers":[{"nameIdentifier":"8394","nameIdentifierScheme":"WEKO"}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2020-12-18"}],"displaytype":"detail","filename":"LC132_1.pdf","filesize":[{"value":"555.7 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"LC132_1.pdf","url":"https://nagasaki-u.repo.nii.ac.jp/record/1787/files/LC132_1.pdf"},"version_id":"a4e8e0be-e07a-4491-9ab5-b12ea6ae72e6"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"pemetrexed","subitem_subject_scheme":"Other"},{"subitem_subject":"bevacizumab","subitem_subject_scheme":"Other"},{"subitem_subject":"lung cancer","subitem_subject_scheme":"Other"},{"subitem_subject":"elderly","subitem_subject_scheme":"Other"},{"subitem_subject":"NSqNSCLC","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"Randomized phase II study of pemetrexed or pemetrexed plus bevacizumab for elderly patients with previously untreated non-squamous non-small cell lung cancer: Results of the Lung Oncology Group in Kyushu (LOGIK1201)","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Randomized phase II study of pemetrexed or pemetrexed plus bevacizumab for elderly patients with previously untreated non-squamous non-small cell lung cancer: Results of the Lung Oncology Group in Kyushu (LOGIK1201)"}]},"item_type_id":"2","owner":"2","path":["9"],"pubdate":{"attribute_name":"公開日","attribute_value":"2020-07-01"},"publish_date":"2020-07-01","publish_status":"0","recid":"1787","relation_version_is_last":true,"title":["Randomized phase II study of pemetrexed or pemetrexed plus bevacizumab for elderly patients with previously untreated non-squamous non-small cell lung cancer: Results of the Lung Oncology Group in Kyushu (LOGIK1201)"],"weko_creator_id":"2","weko_shared_id":-1},"updated":"2023-05-16T03:57:35.797997+00:00"}